Harrow Health Inc

Harrow Health, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development.The Pharmaceutical Compounding segment focuses on the operations of ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in Nashville, TN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Harrow Health Inc anticipates breakout year in 2023 post-successful Q4

Harrow Health Inc's Q4 2022 call showcased a strong performance, emphasizing strategic acquisitions and growth prospects for 2023. While challenges in expense management and pricing strategies exist, the company's leadership is focused on maximizing opportunities and delivering value to stakeholders.

Harrow Health Inc excels in Q1, poised for ophthalmic market leadership

Harrow Health Inc's Q1 2023 earnings call highlighted robust financial performance, a strategic roadmap for market leadership in ophthalmic pharmaceuticals, and positive early indicators for product success. While facing challenges in product formulations and margins, the company's focus on customer feedback and commercialization strategies presents significant growth opportunities.

Harrow Health Inc reports revenue growth driven by key products

Harrow Health Inc's Q2 2023 performance reflects positive revenue growth and a strong market position driven by VEVYE and IHEEZO.
While facing challenges with leverage ratios and net equity, the company's flexible approach and growth outlook offer opportunities for improvement.
Strengthened by recent acquisitions and stakeholder support, Harrow Health is poised for continued growth and market competitiveness.
Investors should monitor the company's financial leverage, revenue drivers, and market strategies for insights into its future performance.

Harrow Health Inc achieves record revenues, eyes market expansion

Harrow Health Inc reported strong financial performance with record revenues and growth in key metrics.
While facing challenges in certain product revenues and the compounding business, the company is optimistic about new product opportunities.
Management's confidence in the company's prospects and goals reflects a positive outlook for stakeholders.

Harrow Health Inc reports stellar Q4 results and eyes market dominance

Harrow Health Inc's Q4 2023 performance reflects robust financial growth, strategic successes, and a resilient market position, setting the stage for continued expansion.
While facing challenges such as a cyber attack impact and operational hurdles, the company's strengths in strategic focus, pricing strategy, and market opportunities position it well for future success.
With a clear vision for growth, a commitment to value creation, and a focus on market dominance in key segments, Harrow Health Inc is poised for sustained growth and profitability in the coming year.

Harrow Health Inc (HROW) achieves record Q3 revenue growth

Harrow Health Inc (HROW) reported strong Q3 performance with record revenue, driven by VEVYE and IHEEZO. The company is focused on sustainable growth, long-term vision, and value creation for stakeholders. Challenges include temporary inventory shortages and limited direct-to-consumer advertising plans.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in Nashville, TN.

Harrow (HROW) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Harrow (HROW) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

Even though the company failed to fit the analysts' expectations for EPS, the company's financial indicators are growing. The company's gross margin is growing, operating expenses are decreasing, and revenue growth rate maintains a positive trend. We expect the company continues to increase both revenue and profitability.

Harrow Health: Our 3rd Quarter Update On This Promising Company

Harrow (HROW) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Earnings Estimates Moving Higher for Harrow (HROW): Time to Buy?

Harrow Health's (HROW) CEO Mark L. Baum on Q3 2021 Results - Earnings Call Transcript

Harrow (HROW) delivered earnings and revenue surprises of 66.67% and 8.34%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Harrow Health (HROW) Beats Q3 Earnings and Revenue Estimates

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced results for the third quarter and nine months ended September 30, 2021. The Company also posted its third quarter Letter to Stockholders and corporate presentation to the “Investors” section of its website, harrowinc.com. “I am pleased to report a fifth consecutive quarter of strong top-line revenue growth for the third quarter of 2021, a quarter which has historicall

Harrow Health Announces Third Quarter 2021 Financial Results

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic‑focused healthcare company, today announced that it will release its financial results for the third quarter and nine months ended September 30, 2021, on Tuesday, November 9, 2021, after the market close. The Company will also post its third quarter Letter to Stockholders to the “Investors” section of its website, harrowinc.com. Harrow Health will host a conference call and live webcast at 4:45 p.m. Eastern Tim

Harrow Health to Announce Third Quarter 2021 Financial Results on November 9, 2021

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow Health, Inc. (Nasdaq: HROW), an ophthalmic-focused healthcare company, and Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing first-in-class medicines for sedation and analgesia, today announced that Harrow Health has provided a $13.5 million senior secured loan to Melt Pharmaceuticals. Melt Pharmaceuticals plans to use the proceeds to conduct its pivotal Phase 2 efficacy study for the company's lead drug candidate, MELT-300,

Harrow Health Provides $13.5 Million Senior Secured Loan to Melt Pharmaceuticals

The company can grow efficiently; as revenue grows, the Cost of Revenue and SG&A expenses as a % of revenue decrease. Management expects this trend to continue. According to The National Eye Institute, over 24 million Americans are affected by cataracts. The market potential allows the company to grow further.

Harrow Health: Good Opportunity For Growth Investors

For an undisclosed amount, Harrow Health Inc (NASDAQ: HROW) has agreed to acquire MAQ-100 U.S. and Canadian commercial rights from Wakamoto Pharmaceutical Co Ltd. MAQ-100 is a preservative-free triamcinolone acetonide ophthalmic injection.

Harrow Health Acquires Japan-Approved Ophthalmic Injection For Undisclosed Sum

NASHVILLE, Tenn. & TOKYO--(BUSINESS WIRE)---- $HROW--Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic‑focused healthcare company, today announced that it has entered into an agreement with Wakamoto Pharmaceutical Co., Ltd. to acquire the U.S. and Canadian commercial rights for drug candidate MAQ-100, a preservative-free triamcinolone acetonide ophthalmic injection. MAQ-100 is marketed and sold by Wakamoto in Japan as MaQaid®. Following Japan's Ministry of Health Labor and Welfare (or MHLW) approval, MaQ

Harrow Health Acquires Ophthalmic Surgical Drug Candidate From Wakamoto Pharmaceutical Co., Ltd.

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced that Mark L. Baum, Chief Executive Officer, and Andrew Boll, Chief Financial Officer, will participate in two upcoming virtual investor conferences. Harrow Health will participate in the H.C. Wainwright Ophthalmology Virtual Conference to be held August 17, 2021. The Company's pre-recorded presentation will be available via a link on the investor relations section of

Harrow Health to Participate in Two Upcoming Virtual Investor Conferences

Harrow Health, Inc. (HROW) CEO Mark Baum on Q2 2021 Results - Earnings Call Transcript

Harrow (HROW) delivered earnings and revenue surprises of 15.38% and 16.02%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Harrow Health (HROW) Reports Q2 Loss, Tops Revenue Estimates

Shares of Harrow Health (NASDAQ:HROW) were flat after the company reported Q2 results. Quarterly Results Earnings per share decreased 1000.00% year over year to ($0.11), which missed the estimate of ($0.03).

Harrow Health: Q2 Earnings Insights

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced record results for the second quarter and first half ended June 30, 2021. The Company also posted its second quarter Letter to Stockholders and corporate presentation to the “Investors” section of its website, harrowinc.com. “We are pleased to report that the second quarter of 2021 was our best financial quarter in company history, including new records in revenues, c

Harrow Health Announces Second Quarter 2021 Financial Results

Harrow Health (HROW) Q2 results are likely to reflect growth coming from the launch of Visionology, the company's direct-to-consumer eyecare platform.

What's in Store for Harrow Health (HROW) in Q2 Earnings?

Harrow (HROW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Harrow Health (HROW) to Report a Decline in Earnings: What to Look Out for

In the latest trading session, Harrow Health (HROW) closed at $8.97, marking a +0.56% move from the previous day.

Harrow Health (HROW) Gains As Market Dips: What You Should Know

Is (HROW) Outperforming Other Medical Stocks This Year?

Is Harrow Health (HROW) Stock Outpacing Its Medical Peers This Year?

NASHVILLE, Tenn. & MENDRISIO, Switzerland--(BUSINESS WIRE)---- $HROW--Harrow Health Acquires Patented Ophthalmic Surgical Drug Candidate from Sintetica

Harrow Health Acquires Patented Ophthalmic Surgical Drug Candidate from Sintetica

NASHVILLE, Tenn., July 26, 2021 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced that it will release its financial results for the second quarter and six months ended June 30, 2021, on Tuesday, August 10, 2021, after the market close. The Company will also post its second quarter Letter to Stockholders to the “Investors” section of its website, harrowinc.com. Harrow Health will host a conference call and live webcast at 4:45 p.m. Eastern Time to discuss the results and provide a business update.

Harrow Health to Announce Second Quarter 2021 Financial Results on August 10, 2021

EMERYVILLE, Calif. & NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW #Avenova--NovaBay partners with ImprimisRx to promote prescription Avenova.

NovaBay Pharmaceuticals Partners with Harrow Health's ImprimisRx® to Promote Prescription Avenova

The heavy selling pressure might have exhausted for Harrow (HROW) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Down 14% in 4 Weeks, Here's Why You Should You Buy the Dip in Harrow (HROW)

BellRing Brands Inc

Henry Schein

West Pharmaceutical Services

Stocks like Henry Schein (HSIC), BellRing Brands (BRBR), Harrow Health (HROW) and West Pharmaceuticals Services (WST) are solid low-beta picks with strong fundamentals.

News for Harrow Health Inc Stock (HROW)